Kymera (NASDAQ: KYMR) stockholder plans 5,500-share Form 144 sale

Rhea-AI Filing Summary

A stockholder of Kymera Therapeutics (KYMR) filed a Form 144 notice to sell 5,500 common shares through Morgan Stanley Smith Barney LLC on or about 01/20/2026. The shares were acquired the same day by exercising stock options for cash, and the planned sale has an aggregate market value of $382,470.00. Kymera had 71,949,027 shares outstanding at the time referenced.

The filing also reports that, during the prior three months, there were Rule 10b5-1 sales for Pamela Esposito of 27,563 common shares on 12/17/2025, generating $2,264,479.00 in gross proceeds. By signing the notice, the seller represents they are not aware of any undisclosed material adverse information about Kymera’s operations.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	5500	382470.00	71949027	01/20/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	01/20/2026	Exercise of Stock Options	Issuer			5500	01/20/2026	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
10b5-1 Sales for PAMELA ESPOSITO 500 North Beacon Street, 4th Floor Watertown MA 02472	Common	12/17/2025	27563	2264479.00

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does Kymera Therapeutics (KYMR) Form 144 filing disclose?

The Form 144 shows that a Kymera Therapeutics stockholder has filed notice to sell 5,500 common shares, which were acquired by exercising stock options for cash on 01/20/2026. The planned sale has an aggregate market value of $382,470.00 and is to be executed through Morgan Stanley Smith Barney LLC on the NASDAQ.

How many Kymera (KYMR) shares are covered by the new Form 144 notice?

The notice covers a proposed sale of 5,500 shares of Kymera common stock. These shares were obtained via an exercise of stock options on 01/20/2026 and are expected to be sold on or about the same date.

What prior Kymera (KYMR) stock sales are reported in the past 3 months?

The filing reports Rule 10b5-1 sales for Pamela Esposito of 27,563 common shares on 12/17/2025, with gross proceeds of $2,264,479.00. These sales are separate from the newly proposed 5,500-share sale.

What is the aggregate market value of the Kymera (KYMR) shares in this Form 144?

The 5,500 Kymera common shares covered by the Form 144 have an aggregate market value of $382,470.00, based on the information in the filing’s securities information section.

How many Kymera (KYMR) shares were outstanding at the time referenced in the Form 144?

The Form 144 lists 71,949,027 Kymera common shares outstanding in the securities information section. This figure provides a baseline context for the size of the proposed 5,500-share sale.

What representations does the Kymera (KYMR) seller make in the Form 144?

By signing the notice, the person for whose account the Kymera shares are to be sold represents that they do not know of any material adverse information about the issuer’s current or prospective operations that has not been publicly disclosed. If relying on a Rule 10b5-1 plan, that representation applies as of the plan adoption or instruction date.